FDA Approves New Treatments for Opioid Overdose, Opioid Use Disorder
May 24th 2023The FDA recently approved Brixadi to treat moderate to severe opioid use disorder in patients who have already started treatment with a transmucosal form of buprenorphine, and have approved Opvee as an emergency treatment to reverse known or suspected opioid overdose in people ages 12 years and older.
FDA Approves First Fecal Microbiota Pill for Recurrent C. diff Infection
April 28th 2023CDI is a leading cause of infections acquired in healthcare settings, including hospitals and nursing homes. After recovering, individuals may get the infection again, and the risk of recurrence increases with each infection.
HyQvia Receives Expanded FDA Approval for Pediatric Primary Immunodeficiency
April 14th 2023HyQvia is the first FDA-approved treatment for primary immunodeficiency (PI) available as a once-a-month subcutaneous injection. Other treatments for PI, while similarly effective, present a greater burden to patients, often requiring more frequent injections or more invasive routes of administration
FDA Grants Emergency Use Authorization to Gohibic for Critically Ill COVID-19 Patients
April 6th 2023The FDA granted the EUA based on the PANAMO phase 3 clinical trial results demonstrating that vilobelimab improved survival compared to placebo, with a 23.9% relative reduction in all-cause mortality at 28 days.